Professional
Added to YB: 2024-10-18
Pitch date: 2024-09-30
NVO [bullish]
Novo Nordisk A/S
-56.91%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 116.46
Price Target
N/A
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
N/A
Polen Global Growth Portfolio Holding: Novo Nordisk A/S
NVO: Mixed safety data in midstage trial for new oral weight loss drug caused weakness. Significant weight loss vs placebo, but limited gains at higher doses with mild-moderate side effects. Market concerns over commercial viability & competition from Eli Lilly. Key next-gen drugs promising; efforts to increase production for high demand.
Read full article (1 min)